Functionally, NK cells in prostate cancer patients exhibit suppression and exhaustion, characterized by the expression of markers such as PD-1 and TIM-3 and the downregulation of activation receptors like NKG2D; this leads to a reduction in both cytotoxic activity and cytokine secretion (43, 44). Here, PDCD1 is linked to prostate carcinoma.